Editors:
- Contains chapters from pioneers in the area of genetic mechanisms, targeted therapy, biology and mouse models for acute myelogenous leukemia
- Includes supplementary material: sn.pub/extras
Part of the book series: Cancer Treatment and Research (CTAR, volume 145)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (15 chapters)
-
Front Matter
-
Back Matter
About this book
Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
Editors and Affiliations
-
Dept. of Genetics, MD Anderson Cancer Center, Houston, USA
Lalitha Nagarajan
About the editor
Bibliographic Information
Book Title: Acute Myelogenous Leukemia
Book Subtitle: Genetics, Biology and Therapy
Editors: Lalitha Nagarajan
Series Title: Cancer Treatment and Research
DOI: https://doi.org/10.1007/978-0-387-69259-3
Publisher: Springer New York, NY
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer-Verlag New York 2010
Hardcover ISBN: 978-0-387-69257-9Published: 18 November 2009
Softcover ISBN: 978-1-4419-1299-2Due: 02 December 2010
eBook ISBN: 978-0-387-69259-3Published: 20 March 2010
Series ISSN: 0927-3042
Series E-ISSN: 2509-8497
Edition Number: 1
Number of Pages: IX, 280
Topics: Oncology, Hematology, Systems Theory, Control